Design Therapeutics Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, has a couple of clinical trial catalysts to watch in the second half of this year.
The company is developing a portfolio of GeneTAC drug candidates aimed at treating genetic diseases caused by repeated DNA sequences. These GeneTAC molecules are a new type of small-molecule medicine designed to target the root cause of disease. They work by either increasing or decreasing the activity of a specific faulty gene, helping to correct the problem rather than just treating symptoms.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.